Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1995 1
1996 1
1997 1
2000 1
2001 2
2002 1
2004 1
2005 1
2006 3
2007 2
2008 2
2009 4
2010 6
2011 3
2012 3
2013 2
2014 2
2015 4
2016 3
2017 3
2018 1
2019 2
2020 2
2021 1
2022 1
2023 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A; INOVATYON study group. Colombo N, et al. Br J Cancer. 2023 Apr;128(8):1503-1513. doi: 10.1038/s41416-022-02108-7. Epub 2023 Feb 9. Br J Cancer. 2023. PMID: 36759720 Free PMC article. Clinical Trial.
Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer.
Nicoletto MO, Baldoni A, Cavallin F, Grego A, Falci C, Nardin M, Mammano E, Lai E, Torri V. Nicoletto MO, et al. Ther Adv Med Oncol. 2023 Jun 21;15:17588359231173181. doi: 10.1177/17588359231173181. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37360767 Free PMC article.
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Colombo N, Tomao F, Benedetti Panici P, Nicoletto MO, Tognon G, Bologna A, Lissoni AA, DeCensi A, Lapresa M, Mancari R, Palaia I, Tasca G, Tettamanzi F, Alvisi MF, Rulli E, Poli D, Carlucci L, Torri V, Fossati R, Biagioli E; BAROCCO study group. Colombo N, et al. Among authors: nicoletto mo. Gynecol Oncol. 2022 Mar;164(3):505-513. doi: 10.1016/j.ygyno.2022.01.015. Epub 2022 Jan 19. Gynecol Oncol. 2022. PMID: 35063281 Clinical Trial.
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
Artioli G, Giannone G, Valabrega G, Maggiorotto F, Genta S, Pignata S, Lorusso D, Cormio G, Scalone S, Nicoletto MO, Greco F, Rossi E, Spagnoletti I, De Giorgi U, Orditura M, Mosconi AM, Kardhashi A, Bogliolo S, Borgato L. Artioli G, et al. Among authors: nicoletto mo. Gynecol Oncol. 2021 Jun;161(3):755-761. doi: 10.1016/j.ygyno.2021.04.014. Epub 2021 Apr 20. Gynecol Oncol. 2021. PMID: 33888336 Free article.
Important role of thiamine in preventing ifosfamide-induced encephalopathy.
Lombardi G, Zustovich F, Nicoletto MO, Donach M, Pastorelli D. Lombardi G, et al. Among authors: nicoletto mo. J Oncol Pharm Pract. 2010 Jun;16(2):135-6. doi: 10.1177/1078155209342134. Epub 2009 Aug 19. J Oncol Pharm Pract. 2010. PMID: 19692431 No abstract available.
51 results